Longevity and Anti-Senescence Therapy Market 2024

The longevity and anti-senescence therapy market size has grown strongly in recent years. It will grow from $26.45 billion in 2023 to $28.13 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to several factors, including increasing life expectancy, heightened awareness of preventive healthcare, breakthroughs in gene therapy, advancements in regenerative medicine, and an aging global population.

The longevity and anti-senescence therapy market size is expected to see strong growth in the next few years. It will grow to $36.11 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period is expected to be driven by factors such as the growing demand for personalized medicine, increased investment in AI-powered health diagnostics, rising consumer interest in wellness and anti-aging products, the convergence of nanotechnology with regenerative therapies, and expanding applications of stem cell treatments. Key trends anticipated in this period include the integration of gene editing and stem cell therapies, the expansion of wearable health technology for personalized care, the rising popularity of nutraceuticals for cellular health, advancements in nanomedicine for targeted anti-aging therapies, and the convergence of biotechnology with regenerative medicine.

The rising incidence of cardiovascular diseases is anticipated to drive the growth of the longevity and anti-senescence therapy market in the coming years. The prevalence of cardiovascular diseases is increasing due to various risk factors, including obesity, diabetes, sedentary lifestyles, poor diet, an aging population, and chronic inflammation. Longevity and anti-senescence therapies aim to address cardiovascular disease by targeting age-related cellular damage and enhancing overall heart health. For example, a report from the American College of Cardiology in August 2022 projected that between 2025 and 2060, all four major cardiovascular risk factors in the United States will rise, with diabetes expected to see the largest increase of 39.3%, reaching 55 million individuals. This will be followed by significant increases in dyslipidemia (27.6% to 126 million), hypertension (25.1% to 162 million), and obesity (18.3% to 126 million). Therefore, the growing prevalence of cardiovascular diseases is a key driver for the longevity and anti-senescence therapy market.

Prominent companies in the longevity and anti-senescence therapy markets are pursuing strategic partnerships to advance their anti-senescence product offerings. These partnerships are collaborative agreements that enable organizations to leverage each other's strengths and resources to achieve shared objectives and enhance their competitive positions. For instance, in July 2024, MDB Capital Holdings LLC, a US-based investment holding company, formed a partnership with Mayo Clinic, a nonprofit medical and surgical clinic, to enhance its anti-senescence platform. The goal of this collaboration is to develop therapies targeting cellular senescence, which is linked to aging and various diseases. The partnership will utilize Mayo Clinic's clinical research expertise alongside MDB Capital's innovative drug development approach, aiming to improve patient outcomes for age-related conditions. This initiative underscores the increasing focus on addressing the biological mechanisms of aging through advanced therapeutic strategies.

In October 2023, Advantage Therapeutics Inc., a US-based company, acquired the intellectual property portfolio of Klogenix LLC for an undisclosed amount. This acquisition enhances Advantage Therapeutics' capabilities and increases its potential to develop impactful therapies for age-related diseases, thereby significantly improving patient outcomes in this vital healthcare sector. Klogenix LLC is a US-based provider of longevity and anti-senescence therapies.

Major companies operating in the longevity and anti-senescence therapy market are AbbVie Inc., BioAge Labs, Unity Biotechnology, Insilico Medicine, Human Longevity Inc., Calico Life Sciences LLC, Recursion Pharmaceuticals, AgeX Therapeutics Inc., Alkahest Inc., CohBar Inc., Stealth Bio Therapeutics, Altos Labs, Navitor Pharmaceuticals Inc., Sierra Sciences LLC, T.A. Sciences Inc., Juvenescence AI Limited, MDB Capital Holdings LLC, Senex Biotechnology, Spotlight Bioscience, Prana Biotechnology Ltd.

North America was the largest region in the longevity and anti-senescence therapy market in 2023. The regions covered in the longevity and anti-senescence therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the longevity and anti-senescence therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Longevity and anti-senescence therapy encompass medical and scientific strategies aimed at extending human lifespan and promoting healthy aging by targeting the biological processes that contribute to aging, cellular damage, and a decline in bodily functions. These therapies focus on mitigating or reversing senescence, a process in which cells lose their ability to divide and function properly, contributing to aging and age-related diseases.

The primary types of longevity and anti-senescence therapies include senolytic drug therapy, gene therapy, cell therapy, mitochondrial therapy, immunotherapy, and others. Senolytic drug therapy specifically involves the use of medications designed to target and eliminate senescent cells, which have ceased to divide and contribute to aging and age-related diseases. This therapy is applied in areas such as longevity enhancement, senescence inhibition, cardiovascular diseases, neurodegenerative disorders, ophthalmic conditions, and cancer treatment, primarily by hospitals and medical service institutions.

The longevity and anti-senescence therapy market research report is one of a series of new reports that provides longevity and anti-senescence therapy market statistics, including longevity and anti-senescence therapy industry global market size, regional shares, competitors with a longevity and anti-senescence therapy market share, detailed longevity and anti-senescence therapy market segments, market trends and opportunities, and any further data you may need to thrive in the longevity and anti-senescence therapy industry. This longevity and anti-senescence therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The longevity and anti-senescence therapy market consists of revenues earned by entities by providing services such as biomarker analysis, platelet-rich plasma (PRP) therapy, exosome therapy, bioidentical hormone replacement therapy, and anti-aging skin treatments. The market value includes the value of related goods sold by the service provider or included within the service offering. The longevity and anti-senescence therapy market also includes sales of peptide-based products, antioxidant and anti-inflammatory products, cognitive enhancers, and skincare and anti-aging cosmetics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.